Selective RNA interference and selective inhibitors demonstrated that this category of AML is strictly dependent on CDK6 for the G1/S transition, leading to the conclusion that CDK6, but not CDK4, is the therapeutic target. Here, CDK6 is linked to acute myeloid leukemia.